CEO Daniel Virnich was paid $1,934,930 in fiscal year 2025, ↑ up 73.0% from fiscal year 2024 (SEC filing 0001193125-26-197350 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,934,930 ↑ Daniel Virnich total, FY2025 | — CEO pay percentile vs peers | 591:1 CEO-to-median pay ratio | 98.89% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
STLN's next annual pay disclosure, estimated June 3, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Daniel Virnich | $475,000 | $212,729 | $1,235,001 | $0 | $0 | $0 | $12,200 | $1,934,930 |
| Chief Executive Officer | ||||||||
| Yale Podnos | 447,000 | 137,625 | 179,080 | 0 | 0 | 0 | 12,200 | 775,905 |
| Chief Medical Officer | ||||||||
| Robert Carter | 390,000 | 106,930 | 225,000 | 0 | 0 | 0 | 12,200 | 734,130 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Daniel Virnich | $1,934,930 | $1,118,358 | $808,129 | ↑ +816,572 |
| Yale Podnos | 775,905 | 610,332 | 591,284 | ↑ +165,573 |
| Robert Carter | 734,130 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Starling Oncology's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper STLN reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name STLN as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Anne McGeorge | Chair of the Board | $424,998 |
| Brad Hively | Independent Director | $315,000 |
| Gabriel Ling | Former director (through FY2025) | $344,999 |
| Karen Johnson | Independent Director | $350,001 |
| Mark Pacala | Independent Director | $340,000 |
| Mohit Kaushal | Independent Director | $369,999 |
| Richard Barasch | Former director (through FY2025) | — |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robert Carter | RSU | 197,368 | — | $702,630 |
| Yale Podnos | RSU | 16,610 | — | 59,132 |
| Yale Podnos | RSU | 41,523 | — | 147,822 |
| Daniel Virnich | RSU | 143,680 | — | 682,000 |
| Robert Carter | RSU | 581 | — | 2,068 |
| Robert Carter | Option | 29,217 | 2 | — |
| Yale Podnos | RSU | 4,241 | — | 15,098 |
| Daniel Virnich | RSU | 1,083,334 | — | 3,856,669 |
| Robert Carter | Option | 2,947 | 7.09 | — |
| Yale Podnos | Option | 21,524 | 7.09 | — |
| Robert Carter | RSU | 11,687 | — | 41,606 |
| Yale Podnos | RSU | 3,541 | — | 12,606 |
| Daniel Virnich | RSU | 148,888 | — | 706,721 |
| Yale Podnos | RSU | 157,088 | — | 559,233 |
| Daniel Virnich | RSU | 57,472 | — | 409,201 |
| Robert Carter | RSU | 15,951 | — | 56,785 |
| Yale Podnos | Option | 17,974 | 1.87 | — |
| Daniel Virnich | RSU | 10,026 | — | 47,590 |
| Daniel Virnich | Option | 50,886 | 1.87 | — |
| Yale Podnos | RSU | 13,148 | — | 46,807 |
| Robert Carter | RSU | 6,381 | — | 22,716 |
| Robert Carter | RSU | 333 | — | 1,185 |
| Daniel Virnich | Option | 372,220 | 2 | — |
| Yale Podnos | Option | 32,869 | 2 | — |
| Robert Carter | Option | 1,687 | 1.87 | — |
Compensation of named executive officers is designed to enable the company to attract and retain talented and experienced executives to lead the company successfully in a competitive environment, with packages primarily consisting of base salary, annual cash incentive bonus, restricted stock unit and stock option awards, and health and welfare benefits.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 25,280,934 | 282,655 | 12,126 | 98.89% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-17 | 98.89%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 591 : 1 |
|---|---|
| CEO total compensation | $1,934,930 |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Anne McGeorgeIndependent · Board Chair · Compensation Committee · Audit Committee | $75,000 | $349,998 | — | — | $0 | $424,998 |
| Mohit KaushalIndependent · Compensation Committee (Chair) · Compliance Committee (Chair) | 75,000 | 294,999 | — | — | 0 | 369,999 |
| Karen JohnsonIndependent · Nominating and Corporate Governance Committee (Chair) · Compliance Committee | 75,000 | 275,001 | — | — | 0 | 350,001 |
| Gabriel LingIndependent · Departed during FY | 75,000 | 269,999 | — | — | 0 | 344,999 |
| Mark PacalaIndependent · Compensation Committee · Audit Committee | 75,000 | 265,000 | — | — | 0 | 340,000 |
| Brad HivelyIndependent · Compliance Committee | 75,000 | 240,000 | — | — | 0 | 315,000 |
| Richard BaraschIndependent · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Daniel VirnichEmployee director | — | — | — | — | — | 0 |
| Kimberly TzoumakasIndependent · Nominating and Corporate Governance Committee · Compliance Committee · Newly elected | — | — | — | — | — | — |
| Mark StolperIndependent · Audit Committee (Chair) · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $75,000 |
|---|---|
| Annual equity retainer | $125,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 20,000 / 20,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $450,000 |
| Equity awards (grant-date value) | $1,694,997 |
| All other compensation | $0 |
| Total cost of the board | $2,144,997 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Starling Oncology | 2025 | Daniel Virnich | $475,000 | $1,235,001 | $0 | $0 | $1,934,930 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Daniel Virnich | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Executive Compensation”. As printed: 1,934,930. Filing ↗machine: r2 · c30 · span 256987–256996 |
| 2 | Section 01, Yale Podnos | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Executive Compensation”. As printed: 775,905. Filing ↗machine: r4 · c30 · span 261505–261512 |
| 3 | Section 01, Robert Carter | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Executive Compensation”. As printed: 734,130. Filing ↗machine: r6 · c30 · span 266022–266029 |
| 4 | Section 07, pay ratio | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “CEO Pay Ratio”. As printed: 591 : 1. Filing ↗ |
| 5 | Section 08, Anne McGeorge | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: 424,998. Filing ↗machine: span 464340–464347 |
| 6 | Section 08, Mohit Kaushal | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: 369,999. Filing ↗machine: span 461596–461603 |
| 7 | Section 08, Karen Johnson | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: 350,001. Filing ↗machine: span 460264–460271 |
| 8 | Section 08, Gabriel Ling | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: 344,999. Filing ↗machine: span 463008–463015 |
| 9 | Section 08, Mark Pacala | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: span 465695–465702 |
| 10 | Section 08, Brad Hively | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: 315,000. Filing ↗machine: span 458907–458914 |
| 11 | Section 08, Richard Barasch | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 08, Daniel Virnich | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 08, Kimberly Tzoumakas | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 14 | Section 08, Mark Stolper | DEF 14A | 2026-04-30 | 0001193125-26-197350 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 15 | Section 06, 2026 vote | Form 8-K | 2026-06-18 | 0001553350-26-000093 | Item 5.07 · say-on-pay result. As reported: 98.89% (votes for as printed: 25,280,934). Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 450,000 + equity 1,694,997 + all other 0 = 2,144,997, summed across the director compensation table rows.machine: formula: Σ = 2,144,997 |
| 18 | Starling Oncology (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197350 | CEO total compensation as printed in Starling Oncology's own proxy. As printed: 1,934,930. Filing ↗machine: r2 · c30 · span 256987–256996 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.